Not two weeks after being acquired, Sage Therapeutics has let go of all of its remaining workforce—338 employees in Cambridge, Massachusetts, according to a Worker Adjustment and Retraining Notification notice. The Cambridge-based biotech’s layoffs will take effect Aug. 22. As of April 22, the company had 338 full-time employees, including 98 members focused on research and development, according to its most recent quarterly report. The workforce reduction comes a few weeks after Sage agreed to be acquired by Supernus Pharmaceuticals. The Maryland-based company offered to buy Sage for $591 million, with a contingent value right that could swell the overall deal value to $795 million based on certain milestones. Sage and Supernus expect to close the transaction in the third quarter.